Literature DB >> 16457909

The sequence of vaccinations and increased female mortality after high-titre measles vaccine: trials from rural Sudan and Kinshasa.

Peter Aaby1, Salah A Ibrahim, Michael D Libman, Henrik Jensen.   

Abstract

OBJECTIVE: West African studies have hypothesized that increased female mortality after high-titre measles vaccine (HTMV) was due to subsequent diphtheria-tetanus-pertussis (DTP) and inactivated polio vaccine (IPV) vaccinations. We tested two deductions from this hypothesis in HTMV studies from rural Sudan and Kinshasa; first, there should be no excess female mortality for HTMV recipients when DTP was not given after HTMV and second, excess female mortality should only be found among those children who received DTP after HTMV. STUDIES: The Sudanese trial randomised 510 children to Edmonston-Zagreb (EZ) HTMV, Connaught HTMV or a control vaccine (meningococcal). Both the Connaught HTMV and the control group received standard measles vaccine at 9 months. In the Kinshasa study 1023 children received one dose of HTMV at 6 months or two doses at 312 and 912 months of age.
FINDINGS: First, the Sudan trial is one of the few randomised studies of measles vaccine; the EZ HTMV group had lower mortality between 5 and 9 months of age than controls, the mortality ratio (MR) being 0.00 (p = 0.030). This effect was not due to prevention of measles infection. Second, both studies provided evidence that HTMV per se was associated with low mortality. In a combined analysis comparing both HTMV groups with controls, the HTMV groups had a MR of 0.09 (0.01-0.71) between 5 and 9 months of age. In Kinshasa, the HTMV recipients who did not receive simultaneous DTP had an annual mortality rate of only 1.0% between 6 months and 3 years of age. Third, the female-male MR was related to subsequent DTP vaccinations. In Kinshasa, the female-male MR was only 0.40 (0.13-1.27) among the HTMV recipients who did not receive further doses of DTP. In Sudan, the female-male mortality ratio in the EZ group was 3.89 (95% CI 1.02-14.83) and the female-male MR increased with number of doses of DTP likely to have been given during follow-up (trend, p = 0.043). Fourth, in Kinshasa, mortality was higher among children who had received HTMV and DTP simultaneously than among children who had received HTMV alone (MR = 5.38 (1.37-21.2)).
CONCLUSIONS: Measles vaccine is associated with non-specific beneficial effects. When not given with DTP, HTMV per se was associated with low mortality. Increased female mortality was not found among children who did not receive DTP after HTMV. Hence, our deductions were supported and the sequence or combination of vaccinations may have an effect on sex-specific mortality patterns in low-income countries.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16457909     DOI: 10.1016/j.vaccine.2006.01.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  Penta is associated with an increased female-male mortality ratio: cohort study from Bangladesh.

Authors:  Syed Manzoor Ahmed Hanifi; Sofie Biering-Sørensen; Aksel Karl Georg Jensen; Peter Aaby; Abbas Bhuiya
Journal:  Hum Vaccin Immunother       Date:  2020-06-23       Impact factor: 3.452

Review 2.  The challenge of assessing infant vaccine responses in resource-poor settings.

Authors:  Katie L Flanagan; Sarah Burl; Barbara L Lohman-Payne; Magdalena Plebanski
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

Review 3.  A narrative review of nonspecific effects of pediatric vaccines on child mortality and morbidity.

Authors:  Muna Omar; Khitam Muhsen
Journal:  Hum Vaccin Immunother       Date:  2021-11-30       Impact factor: 3.452

4.  Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Carlito Balé; Andreas Andersen; Amabelia Rodrigues; Henrik Ravn; Ida M Lisse; Christine S Benn; Hilton C Whittle
Journal:  BMJ       Date:  2010-11-30

5.  Sequence patterns in the resolution of clinical instabilities in community-acquired pneumonia and association with outcomes.

Authors:  Gavin W Hougham; Sandra A Ham; Gregory W Ruhnke; Elizabeth Schulwolf; Andrew D Auerbach; Jeffrey L Schnipper; Peter J Kaboli; Tosha B Wetterneck; David Gonzalez; Vineet M Arora; David O Meltzer
Journal:  J Gen Intern Med       Date:  2013-10-03       Impact factor: 5.128

6.  Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial.

Authors:  Peter Aaby; Henrik Ravn; Adam Roth; Amabelia Rodrigues; Ida Maria Lisse; Birgitte Rode Diness; Karen Rokkedal Lausch; Najaaraq Lund; Julie Rasmussen; Sofie Biering-Sørensen; Hilton Whittle; Christine Stabell Benn
Journal:  Arch Dis Child       Date:  2012-02-13       Impact factor: 3.791

7.  Vaccination coverage and out-of-sequence vaccinations in rural Guinea-Bissau: an observational cohort study.

Authors:  Linda Hornshøj; Christine Stabell Benn; Manuel Fernandes; Amabelia Rodrigues; Peter Aaby; Ane Bærent Fisker
Journal:  BMJ Open       Date:  2012-11-19       Impact factor: 2.692

8.  The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Amabelia Rodrigues; Christine S Benn; Hilton Whittle
Journal:  BMJ Open       Date:  2012-07-19       Impact factor: 2.692

9.  Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries.

Authors:  Peter Aaby; Christine Benn; Jens Nielsen; Ida Maria Lisse; Amabelia Rodrigues; Henrik Ravn
Journal:  BMJ Open       Date:  2012-05-22       Impact factor: 2.692

10.  Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial.

Authors:  Cesário L Martins; May-Lill Garly; Carlito Balé; Amabelia Rodrigues; Henrik Ravn; Hilton C Whittle; Ida M Lisse; Peter Aaby
Journal:  BMJ       Date:  2008-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.